Related Experiment Video
Updated: Jun 23, 2025
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Diapocynin treatment induces functional and structural improvements in an advanced disease state in the mdx5Cv mice
Ghali Guedira1, Olivier Petermann1, Leonardo Scapozza1
1Pharmaceutical Biochemistry/Chemistry Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
Abstract:
Duchenne muscular dystrophy (DMD) is the most common muscular disorder affecting children. It affects nearly 1 male birth over 5000. Oxidative stress is a pervasive feature in the pathogenesis of DMD. Recent work shows that the main generators of ROS are NADPH oxidases (NOX), suggesting that they are an early and promising target in DMD. In addition, skeletal muscles of mdx mice, a murine model of DMD, overexpress NOXes. We investigated the impact of diapocynin, a dimer of the NOX inhibitor apocynin, on the chronic disease phase of mdx5Cv mice. Treatment of these mice with diapocynin from 7 to 10 months of age resulted in decreased hypertrophy of several muscles, prevented force loss induced by tetanic and eccentric contractions, improved muscle and respiratory functions, decreased fibrosis of the diaphragm and positively regulated the expression of disease modifiers. These encouraging results ensure the potential role of diapocynin in future treatment strategies.
Insights
Diapocynin treatment improved muscle and respiratory functions in Duchenne muscular dystrophy (DMD) mice. This NOX inhibitor shows potential for future DMD therapeutic strategies.
Area of Science:
- Biochemistry
- Genetics
- Physiology
Background:
- Duchenne muscular dystrophy (DMD) is a common childhood disorder affecting 1 in 5000 male births.
- Oxidative stress, driven by NADPH oxidases (NOX), is central to DMD pathogenesis.
- Skeletal muscles in mdx mice, a DMD model, exhibit NOX overexpression.
Purpose of the Study:
- To investigate the therapeutic potential of diapocynin, a NOX inhibitor, in the chronic phase of Duchenne muscular dystrophy.
- To assess diapocynin's effects on muscle function, fibrosis, and disease modifiers in mdx mice.
Main Methods:
- Mdx mice were treated with diapocynin from 7 to 10 months of age.
- Evaluated muscle hypertrophy, force generation during contractions, muscle and respiratory functions, and diaphragm fibrosis.
- Analyzed the expression of disease-modifying genes.
Main Results:
- Diapocynin treatment reduced muscle hypertrophy and prevented force loss in mdx mice.
- Significant improvements were observed in muscle and respiratory functions.
- Fibrosis in the diaphragm decreased, and disease modifier expression was positively regulated.
Conclusions:
- Diapocynin demonstrates significant therapeutic benefits in a murine model of Duchenne muscular dystrophy.
- These findings highlight diapocynin as a promising candidate for future DMD treatment strategies.
- Targeting NOX enzymes offers a viable approach for managing DMD progression.
